Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
19 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Damora Therapeutics, Inc.’s names, not what it holds today.
Patents granted
19
19 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 1 in 2023
Applications published
28
since 2001, to Dec 31, 2025
Names they are printed under
2
a subsidiary
By yearGrantedApplications published
'15'16'17'18'19'20'21'22'23'24
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals3
Organic fine chemistry3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
PharmAkea, Inc. a subsidiary
named as the applicant on its applications, in US
25 publishedPHARMAKEA, INC. a subsidiary
US, as the owner printed on each patent
3 publishedNames not counted (2)
Galecto Biotech AB
Most of its patents print DK; this name counts in SE. 28 granted and 41 published under it are not counted.
Galecto Biotech AB
Most of its patents print DK; this name counts in SE. 0 granted and 44 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Oct 24, 2023 | 11,793,797 | Uses of a lysyl oxidase-like 2 inhibitor | Pharmaceuticals | PHARMAKEA, INC. |
| Oct 4, 2022 | 11,459,309 | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making | Organic fine chemistry | PHARMAKEA, INC. |
| Jun 14, 2022 | 11,358,936 | Lysyl oxidase-like 2 inhibitors and uses thereof | Organic fine chemistry | PHARMAKEA, INC. |
| May 31, 2022 | 11,345,676 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | Pharmaceuticals | PHARMAKEA, INC. |
| Jul 27, 2021 | 11,072,585 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | Organic fine chemistry | PHARMAKEA, INC. |
| Jul 13, 2021 | 11,058,676 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | Pharmaceuticals | PHARMAKEA, INC. |
| Sep 15, 2020 | 10,774,069 | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making | Organic fine chemistry | PHARMAKEA, INC. |
| Sep 8, 2020 | 10,766,860 | Lysyl oxidase-like 2 inhibitors and uses thereof | Organic fine chemistry | PHARMAKEA, INC. |
| Mar 17, 2020 | 10,588,900 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | Pharmaceuticals | PHARMAKEA, INC. |
| Feb 25, 2020 | 10,570,094 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | Organic fine chemistry | PHARMAKEA, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 19, 2024 | 2024/0415824 | USES OF A LYSYL OXIDASE-LIKE 2 INHIBITOR | Pharmaceuticals | PHARMAKEA, INC. |
| Jun 17, 2021 | 2021/0177820 | USES OF A LYSYL OXIDASE-LIKE 2 INHIBITOR | Pharmaceuticals | PharmAkea, Inc. |
| Jun 10, 2021 | 2021/0171465 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Organic fine chemistry | PharmAkea, Inc. · patent 11,358,936 granted from it |
| Nov 19, 2020 | 2020/0361901 | CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING | Organic fine chemistry | PharmAkea, Inc. · patent 11,459,309 granted from it |
| Apr 16, 2020 | 2020/0115341 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Organic fine chemistry | PharmAkea, Inc. · patent 11,072,585 granted from it |
| Feb 13, 2020 | 2020/0048218 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | Pharmaceuticals | PharmAkea, Inc. · patent 11,345,676 granted from it |
| Jan 23, 2020 | 2020/0022972 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmaceuticals | PHARMAKEA, INC. · patent 11,058,676 granted from it |
| Jul 4, 2019 | 2019/0202805 | CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING | Organic fine chemistry | PharmAkea, Inc. · patent 10,774,069 granted from it |
| Jun 27, 2019 | 2019/0192697 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | Pharmaceuticals | PharmAkea, Inc. |
| Jun 27, 2019 | 2019/0192495 | USES OF A LYSYL OXIDASE-LIKE 2 INHIBITOR | Pharmaceuticals | PharmAkea, Inc. · patent 11,793,797 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.